Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady GrowthDecision ResourcesJune 14, 2006 24 Pages - SKU: DECR1305277 |
|
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market. In this report, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We discuss the current treatments and promising late-stage agents in development for CLL, as well as the market outlook though 2010. Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
- Biotechnology
- Antibody Technologies
- Life Sciences
- Pharmaceuticals
- Pharmaceuticals
- Biopharmaceuticals
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
